Role of Leptin in Non-Alcoholic Fatty Liver Disease

• Main Authors: Carlos Jiménez-Cortegana, Alba García-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad López, Gonzalo Alba, Víctor Sánchez-Margalet
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Biomedicines
• Subjects: fatty liver; steatohepatitis; obesity; metabolic syndrome; leptin
• Online Access: https://www.mdpi.com/2227-9059/9/7/762

Non-alcoholic fatty liver disease (NAFLD), which affects about a quarter of the global population, poses a substantial health and economic burden in all countries, yet there is no approved pharmacotherapy to treat this entity, nor well-established strategies for its diagnosis. Its prevalence has been rapidly driven by increased physical inactivity, in addition to excessive calorie intake compared to energy expenditure, affecting both adults and children. The increase in the number of cases, together with the higher morbimortality that this disease entails with respect to the general population, makes NAFLD a serious public health problem. Closely related to the development of this disease, there is a hormone derived from adipocytes, leptin, which is involved in energy homeostasis and lipid metabolism. Numerous studies have verified the relationship between persistent hyperleptinemia and the development of steatosis, fibrinogenesis and liver carcinogenesis. Therefore, further studies of the role of leptin in the NAFLD spectrum could represent an advance in the management of this set of diseases.